Locations:
May 21, 2025/News Releases

Cleveland Clinic Receives $5 Million Grant to Lead Biorepository Coordinating Center for Cystic Fibrosis Lung Transplant Consortium

Grant renewal from Cystic Fibrosis Foundation will further efforts to study common complications of lung transplantation and improve outcomes for patients

Illustration of the lungs

Cleveland Clinic has been awarded a $5 million grant from the Cystic Fibrosis Foundation to continue its role as the Biorepository Coordinating Center for the Cystic Fibrosis Lung Transplant Consortium until 2030. The coordinating center provides the infrastructure to support research to improve understanding of the factors that affect lung transplant outcomes.

The initiative, which includes 15 participating institutions in North America, is led by Maryam Valapour, M.D., M.P.P., director of Lung Transplant Outcomes at Cleveland Clinic, and Suzy Comhair, Ph.D., scientific director of Cleveland Clinic’s Biorepository and associate professor in the department of inflammation and immunity.

Since its inception, the center has led this prospective, longitudinal study of lung transplant recipients. The study collects biological specimens and clinical data at key milestones following transplantation, with all data linked to the Cystic Fibrosis Lung Transplant Consortium registry.

The ongoing effort enables future research studies to access these biospecimens and data to investigate the causes of and potential treatments for Chronic Lung Allograft Dysfunction (CLAD). This serious and common complication is the primary cause of lung failure and mortality after lung transplantation.

“This funding will allow Cleveland Clinic to build on the successful work of the past five years leading the Cystic Fibrosis Lung Transplant Consortium’s efforts to study the causes and treatment of CLAD,” said Dr. Valapour. “Our hope is that, through this initiative, we can improve long-term outcomes after lung transplant—a critical treatment option for those with advanced lung disease.”

The Cystic Fibrosis Foundation created the Cystic Fibrosis Lung Transplant Consortium in 2017 to establish a network of research centers that contribute specialized expertise, clinical data, and biospecimens to accelerate research into CLAD.

“We are proud to serve as the hub of the Cystic Fibrosis Lung Transplant Consortium and be part of a clinical and translational research network that brings together 15 lung transplant centers across the United States and Canada,” said Dr. Comhair. “This multi-institutional team is collaborating closely to advance our understanding of CLAD and develop new therapies that will enhance patient outcomes.”

The renewed funding for the Biorepository Coordinating Center will support the continued collection and curation of clinical data and specimens, as well as the expansion of research goals. The center also will update its program objectives to reflect evolving scientific priorities and ensure that the biorepository continues to serve as a critical resource for qualified researchers studying CLAD.

While the median life expectancy for people with cystic fibrosis has improved significantly in recent decades, long-term outcomes after lung transplant have only modestly improved, largely due to the persistent challenge of CLAD.

Furthermore, variations in transplant-candidate selection and post-transplant care point to opportunities for identifying best practices that could improve both access to transplantation and patient outcomes.

About Cleveland Clinic

Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation, Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. Cleveland Clinic is consistently recognized in the U.S. and throughout the world for its expertise and care. Among Cleveland Clinic’s 83,000 employees worldwide are more than 6,600 salaried physicians and researchers, and 21,900 registered nurses and advanced practice providers, representing 140 medical specialties and subspecialties. Cleveland Clinic is a 6,725-bed health system that includes a 173-acre main campus near downtown Cleveland, 23 hospitals, 300 outpatient facilities, including locations in northeast Ohio; Florida; Las Vegas, Nevada; Toronto, Canada; Abu Dhabi, UAE; and London, England. In 2025, there were 15.9 million outpatient encounters, 343,000 hospital admissions and observations, and 336,000 surgeries and procedures throughout Cleveland Clinic’s health system. Visit us at clevelandclinic.org. Follow us at x.com/CleClinicNews. News and resources are available at newsroom.clevelandclinic.org.

Editor’s Note: Cleveland Clinic News Service is available to provide broadcast-quality interviews and B-roll upon request.

Latest from the Newsroom

Photo of scale wit a tape measure.

Cleveland Clinic Study Identifies Best Treatment Strategies for Weight Loss After Stopping GLP-1 Drugs

Cleveland Clinic's new teaching kitchen and food pantry at the Langston Hughes Community Health & Education Center

Cleveland Clinic Opens Teaching Kitchen and Food Pantry on Cleveland's East Side

VeloSano riders

$20.2 Million Raised for VeloSano, Funding Cancer Research at Cleveland Clinic in 2026

Photo of spine imaging.

Cleveland Clinic Expands Orthopaedic Care in the Mahoning Valley Through Acquisition of Youngstown Orthopaedic Associates Practice

Lobby of new Toronto location

Cleveland Clinic Canada Moves to New Downtown Toronto Location

Artist's rendering of gene therapy for high triglycerides.

Gene Editing Therapy Trial Dramatically Lowers Dangerous Blood Fat Levels

Artist's illustration of gene editing

Cleveland Clinic First-in-Human Trial Shows Gene-Silencing Therapy for High Cholesterol to Be Safe and Effective

Medical illustration of lipoprotein(a) molecule

Cleveland Clinic Trial Shows Novel Lipoprotein(a) Drug Did Not Reduce Major Cardiovascular Events After Nearly 5 Years